Abstract

Introduction: To assess the benefits of prophylactic ascorbic acid to reduce development of contrast-induced nephropathy (CIN) in patients undergoing percutaneous coronary interventions (PCIs).Methods: PubMed was searched with the search strategy of (vitamin C OR ascorbic acid) AND (kidney OR renal) AND (PCI OR percutaneous coronary Intervention OR cardiac OR heart). There was no date and language restriction for the selection of the articles.All the randomized controlled trials (RCTs) which investigated the efficacy of AA on reducing the incidence of CIN were included. Totally 267 articles were found at the initial search; however, only 10 RCTs were eligible to be included. Odds ratio is presented for each of the articles as the effect size.Conclusions: Controversial findings were reported on the efficacy of AA on reducing the CIN development; due to various limitations of these articles, there is still great debate among the cardiology and radiology communities, which increases the need for further researches.

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call